Dr Carrie van der Weyden

The Hudson Medical Research Institute

This Project is a collaboration between the Hudson Medical Research Institute and Peter MacCallum Cancer Centre to develop a CAR-T cell therapy for cutaneous T-cell lymphoma, targeting a protein which is selectively overexpressed on skin lymphoma cells. The Hudson Medical Research Institute have successfully developed a CAR-T product targeting this protein which has been effective in killing skin lymphoma cells in preliminary laboratory experiments, with further research underway. Additionally, this protein is also overexpressed in other malignancies such as ovarian and stomach cancers, meaning that this CAR-T product might have potential applications in other cancer types.

This research is moving towards developing a world-first clinical trial of this cellular product in patients with cutaneous T-cell lymphoma.